

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): March 7, 2016

**Alliqua BioMedical, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-36278  
(Commission File Number)

58-2349413  
(IRS Employer  
Identification No.)

1010 Stony Hill Road  
Suite 200  
Yardley, PA 19067  
(Address of principal executive offices)

19067  
(Zip Code)

Registrant's telephone number, including area code: (215) 702-8550

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 7, 2016, Andrew Africk informed the board of directors of Alliqua BioMedical, Inc. (the “Company”) that he will not stand for re-election as a director at the Company’s 2016 annual meeting of stockholders (the “Annual Meeting”). Mr. Africk will continue to serve on the Company’s board of directors until the Annual Meeting, which is when his term of office as a director will expire. Mr. Africk’s decision not to stand for re-election was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, or any other matter.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALLIQUA BIOMEDICAL, INC.**

Dated: March 10, 2016

By: /s/ Brian Posner  
Name: Brian Posner  
Title: Chief Financial Officer

---